immatics biotechnologies GmbH - Asset Resilience Ratio
immatics biotechnologies GmbH (4A3) has an Asset Resilience Ratio of 18.50% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of immatics biotechnologies GmbH for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how immatics biotechnologies GmbH's Asset Resilience Ratio has changed over time. See immatics biotechnologies GmbH (4A3) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down immatics biotechnologies GmbH's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see immatics biotechnologies GmbH (4A3) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €95.92 Million | 18.5% |
| Total Liquid Assets | €95.92 Million | 18.50% |
Asset Resilience Insights
- Good Liquidity Position: immatics biotechnologies GmbH maintains a healthy 18.50% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
immatics biotechnologies GmbH Industry Peers by Asset Resilience Ratio
Compare immatics biotechnologies GmbH's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for immatics biotechnologies GmbH (2019–2024)
The table below shows the annual Asset Resilience Ratio data for immatics biotechnologies GmbH.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 52.82% | €367.70 Million ≈ $429.88 Million |
€696.15 Million ≈ $813.87 Million |
+12.15pp |
| 2023-12-31 | 40.67% | €207.42 Million ≈ $242.50 Million |
€509.96 Million ≈ $596.20 Million |
-11.72pp |
| 2022-12-31 | 52.40% | €213.69 Million ≈ $249.82 Million |
€407.82 Million ≈ $476.78 Million |
+45.46pp |
| 2021-12-31 | 6.94% | €12.12 Million ≈ $14.17 Million |
€174.65 Million ≈ $204.18 Million |
-2.66pp |
| 2020-12-31 | 9.60% | €24.45 Million ≈ $28.58 Million |
€254.65 Million ≈ $297.71 Million |
-2.33pp |
| 2019-12-31 | 11.93% | €16.02 Million ≈ $18.73 Million |
€134.28 Million ≈ $156.98 Million |
-- |
About immatics biotechnologies GmbH
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapie… Read more